NXTC Projected Dividend Yield
NextCure Inc ( NASDAQ : NXTC )NextCure is a biopharmaceutical company focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Co.'s product candidates include: NC410, which is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for Leukocyte Associated Immunoglobulin Like Receptor 1 (LAIR-1) and is designed to block immune suppression mediated by LAIR-1; NC762, which is a monoclonal antibody that binds specifically to human B7 homolog 4 protein, a protein expressed on multiple tumor types; and NC525 (LAIR-1 mAb), which selectively targets Acute Myeloid Leukemia, blast cells and leukemic stem cells. 20 YEAR PERFORMANCE RESULTS |
NXTC Dividend History Detail NXTC Dividend News NXTC Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |